Cushing’s Syndrome due to Bilateral Adrenocortical Adenomas with Different Pathological Features

Hideki Tamura, Hitoshi Sugihara, Shiro Minami, Naoya Emoto, Tamotsu Shibasaki, Yujin Shuto, Kazuo Shimizu*, Yukari Gomi**, Hironobu Sasano*** and Ichiji Wakabayashi

A 48-year-old woman with Cushing’s syndrome due to bilateral adrenocortical adenomas is reported. The patient presented with a typical Cushingoid appearance. The serum cortisol level was elevated with loss of the diurnal rhythm and the plasma adrenocorticotropic hormone (ACTH) level was undetectable. Dynamic testing showed no suppression of urinary 17-OHCS by high-dose dexamethasone and no stimulation by metyrapone. An abdominal computed tomography (CT) scan showed bilateral adrenal tumors. Bilateral adrenalectomy was performed. The right adrenal gland contained a tumor that was encapsulated and consisted mainly of compact cells. The surrounding cortex was atrophic. The left adrenal gland contained an encapsulated tumor composed predominantly of clear cells. There were numerous small adrenocortical nodules in the surrounding cortex. Immunohistochemical analysis of steroidogenic enzymes (P450scc, 3β-HSD, P450c21, P450c17 and P450c11) was performed. Immunoreactivity of all the enzymes was intense in the compact cells of the right adrenocortical adenoma, while the adjacent non-neoplastic cortex was negative for the enzymes. In the left adrenal tumor, the immunoreactivity of 3β-HSD was intense, while that of P450c17 was weak. In the adrenocortical nodules, 3β-HSD activity was sporadically observed. G protein genes encoding Gs α and Gi2 were examined for activating mutations at codons 201 and 227 (Gs α) and codons 179 and 205 (Gi2 α) in the bilateral adrenal tumors, but no mutations were found. The bilateral adenomas of this patient showed marked differences in microscopic and immunohistochemical studies, suggesting that the capacity of steroidogenesis differs between the right and left tumors. (Internal Medicine 36: 804-809, 1997)

Key words: immunohistochemistry, G protein gene mutation

Introduction

Endogenous Cushing’s syndrome can be divided into two general types: adrenocorticotropic hormone (ACTH)-dependent and ACTH-independent. The majority of ACTH-independent Cushing’s syndrome is due to a unilateral adrenocortical lesion. ACTH-independent Cushing’s syndrome is occasionally caused by bilateral adrenocortical lesions. These include primary pigmented nodular adrenocortical disease (PPNAD), ACTH-independent bilateral macronodular adrenocortical hyperplasia (AIMAH) and bilateral adrenocortical tumors. The endocrine and pathologic features of PPNAD and AIMAH have been well documented (1-6). However, the pathogenesis of bilateral adrenocortical adenomas appears to be heterogeneous (7-13). In the present case, diagnosed as Cushing’s syndrome due to bilateral adenomas, microscopic studies and immunohistochemical studies for steroidogenic enzymes showed marked differences between the right and left tumors.

In the past few years, mutations in G proteins have been identified as the causes of several endocrine diseases (14). G protein genes encoding Gs α and Gi2 were also examined for activating mutations at codons 201 and 227 (Gs α) and codons 179 and 205 (Gi2 α) in the adrenal tumor tissues.

Case Report

A 48-year-old woman was hospitalized because of Cushingoid appearance. For several years, she had been amenorrheal and was being treated for hypertension. She had
Cushing’s Syndrome due to Adrenal Adenomas

The patient had gained 17 kg over the last 5 years. Dependent edema had been noted for 2 years. The laboratory data were consistent with ACTH-independent Cushing’s syndrome, as described below. She was referred to the Nippon Medical School Hospital in January 1995. She had undergone thyroidectomy for papillary carcinoma of the thyroid 5 years earlier. Her mother died of lung cancer.

The patient’s height was 163 cm, and her body weight was 84 kg. The blood pressure was 128/70 mmHg while she was on an antihypertensive drug. She had central obesity, moon face, thin skin, easy bruising, striae cutis, hirsutism and pitting edema of the lower extremities. There was no cutaneous hyperpigmentation or spotty pigmentation. Radiographs of the chest showed mild cardiomegaly, while those of the thoracic and lumbar vertebrae revealed osteoporosis.

The initial laboratory data were as follows. The white blood cell count was 11,300 per cubic millimeter with a shift to the left, and 0% eosinophils. In addition, serum potassium was 3.6 mEq/l, fasting blood glucose 79 mg/dl, morning serum cortisol 31 μg/dl, morning plasma ACTH not detectable (lower than 5 pg/ml), urinary cortisol 414 μg/day (normal 20–100 μg/day), serum dehydroepiandrosterone sulfate 626 ng/ml (normal 500–2,500 ng/ml), plasma renin activity 1.1 ng/ml/h, and serum aldosterone 4.2 ng/dl. The results of endocrine studies of the hypothalamic-pituitary-adrenal axis are shown in Table 1. The diurnal rhythm of serum cortisol was lost. The urinary 17-OHCS did not respond to the administration of dexamethasone or metyrapone (Table 1). Administration of 100 μg of human corticotropin-releasing hormone (CRH) did not influence the level of serum cortisol or plasma ACTH (lower than 5 pg/ml). Oral administration of 75 g of glucose also did not influence the serum cortisol level (Table 1). Computed tomography (CT) scans of the abdomen showed bilateral adrenal tumors (Fig. 1), while CT scans of the sella turcica revealed nothing remarkable. An iodocholesterol scintigram showed bilateral adrenal activity (Fig. 2).

On February 1995, bilateral total adrenalectomy was performed. The right adrenal gland weighed 6.8 g and contained an oval-shaped brown tumor (3.5 × 2.8 cm) (Fig. 3). The tumor was encapsulated and consisted mainly of compact cells (Fig. 4A), while the surrounding cortex was atrophied (Fig. 4B). The left adrenal gland weighed 5.8 g and contained a round tumor (2.4 × 2.2 cm) (Fig. 3). The major tumor was encapsulated and composed predominantly of clear cells (Fig. 4C). The surrounding cortex contained numerous small adrenocortical cell nodules, and intervening adrenocortical tissue was not clearly found (Fig. 4D). Microscopic examination confirmed that the bilateral tumors were benign adrenocortical adenomas. Since the bilateral adrenalectomy, the patient has been on dexamethasone (0.5 mg/day) or prednisolone (5 mg/day). The plasma ACTH level has been below or only slightly above the limit of detection of the assay (5 pg/ml).

Immunohistochemical analyses of the following steroidogenic enzymes [cholesterol side chain cleavage (P450scc), 3β-hydroxysteroid dehydrogenase (3β-HSD), 21-hydroxylase (P450c21), 17α-hydroxylase (P450c17) and 11β-hydroxylase (P450c11)] were performed according to the methods described previously (13). Immunoreactivity of all the enzymes

<table>
<thead>
<tr>
<th>Table 1. Results of Endocrine Studies of Pituitary-Adrenal Axis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum cortisol (μg/dl)</td>
</tr>
<tr>
<td>Dexamethasone suppression test†</td>
</tr>
<tr>
<td>basal level (day 1)</td>
</tr>
<tr>
<td>4 mg/day (day 2)</td>
</tr>
<tr>
<td>4 mg/day (day 3)</td>
</tr>
<tr>
<td>Metyrapone test‡</td>
</tr>
<tr>
<td>basal level (day 1)</td>
</tr>
<tr>
<td>basal level (day 2)</td>
</tr>
<tr>
<td>4.5 g/day (day 3)</td>
</tr>
<tr>
<td>1-day late (day 4)</td>
</tr>
<tr>
<td>CRH test*</td>
</tr>
<tr>
<td>cortisol (μg/dl)</td>
</tr>
<tr>
<td>ACTH (pg/ml)</td>
</tr>
<tr>
<td>Oral glucose§</td>
</tr>
<tr>
<td>cortisol (μg/dl)</td>
</tr>
</tbody>
</table>

†Dexamethasone was administered orally 1 mg every 6 h on days 2 and 3. ‡750 mg of metyrapone was administered orally every 4 h on day 3. *100 μg of human CRH was administered intravenously at 0 min. §75 g glucose was administered orally at 0 min. Plasma ACTH was undetectable by the ACTH assays (lower than 5 pg/ml).
was intense in the compact cells of the right adrenocortical adenoma, while it was negative in the adjacent non-neoplastic cortex. Immunoreactivity of all the steroidogeneic enzymes was also detected in the major left adrenal tumor, with marked 3β-HSD and weak P450c17 immunoreactivity (Figs. 5, 6). In the adrenocortical nodules, 3β-HSD immunoreactivity was sporadically observed (Fig. 5).

Genomic DNA from the bilateral tumor tissues obtained at the time of surgery was extracted by standard procedures. DNA was amplified by the polymerase chain reaction (PCR) with 2 sets of primers flanking codons 201 and 227 of the human Gs α gene and codons 179 and 205 of the human Gi2 α gene (14). The PCR mixture contained 2.5 U Taq DNA polymerase and 30 pmol of each primer. Amplification was accomplished in 30 cycles of 1 minute at 94°C, 2 minutes at 58°C and 3 minutes at 72°C in a Perkin-Elmer Cetus Thermocycler. Amplified DNA was purified and subjected to direct DNA sequence using the Sequenase kit (U.S. Biochemicals, Cleveland, OH). Genomic DNA from each tumor showed only the wild-type sequence at codons 201 and 227 of the human Gs α gene. We then looked for mutations of the human Gi2 α gene. No mutations were found in codon 179 or codon 205 of the human Gi2 α gene.

**Discussion**

Bilateral adrenal adenomas causing Cushing’s syndrome in the present case showed marked differences between the right and left tumors in the histological studies and immunohistochemical studies for steroidogenic enzymes. The features of the
Cushing's Syndrome due to Adrenal Adenomas

right adrenal adenoma were typical of ACTH-independent adrenal adenomas causing Cushing's syndrome. In contrast, the left adrenal gland harbored one large adenoma which showed different histological features and patterns of expression of steroidogenic enzymes compared to the right adrenal tumor. In addition, numerous small adrenocortical nodules expressing steroidogenic enzymes existed, and the intervening cortical tissues were not found in the left adrenal. It is speculated that, in this patient, the right adrenocortical adenoma might efficiently produce and dominantly secrete cortisol as compared to the left adrenal tumor. These features of bilateral adenoma of our patient are clearly different from those described for PPNAD or AIMAH. For instance, in AIMAH, the histological features reveal a combination of cord-forming clear cells and nest-forming compact cells (15), and P450c17 and 3β-HSD are weakly expressed in the clear cells and compact cells, respectively (2-4). In PPNAD, the adrenal cortex consists mainly of compact cells with dispersed micronodules which strongly express all steroidogenic enzymes (1).

Bilateral macronodular hyperplasia is found in older patients with long-standing Cushing's disease (16). The nodules compress the surrounding cortex, which is, without exception, hyperplastic. A transition from pituitary-dependent to ACTH independent solitary adrenocortical adenoma has been postulated (17). It is still uncertain whether there is ever progression

Figure 4. HE-stained sections of the right adrenal glands (A, B) (x150). The tumor consisted mainly of compact cells (A), the surrounding cortex was atrophic (B). HE-stained sections of the left adrenal glands (C, D) (x150). The major tumor was encapsulated predominantly composed of clear cells (C), while adrenocortical nodules in the surrounding cortex were also composed of clear cells (D).

Figure 5. Immunoreactivity of 3β-HSD in the left adrenal gland (x200). Intense immunoreactivity was observed in the tumor (A), but sporadically expressed in the attached nodules (B).
to true autonomy. Other mechanisms have been proposed for the development of bilateral adrenocortical adenomas or nodular adrenal hyperplasia. An aberrant adrenal sensitivity to gastric inhibitory polypeptide (GIP) underlies Cushing's syndrome with nodular adrenal hyperplasia (18, 19). This does not appear to apply to this case, since the plasma cortisol did not increase in response to oral glucose administration accompanying the increased GIP secretion (18, 19).

G protein mutations occur in a wider range of endocrine conditions than has been recognized hitherto (20). Activating mutations of the α-subunits of Gs and Gi2 α that convert these subunits into putative oncogenes have been described in patients with multiple endocrinopathies, including nodular and hyperplastic adrenal glands accompanied by pituitary adenoma (14). However, we could not detect activating mutations at codons 201 and 227 of the Gs α subunit or codons 179 or 205 of the Gi2 α subunit in the tumor tissue from the present case.

References


Cushing's Syndrome due to Adrenal Adenomas

Endocrinol Metab 58: 25, 1984.


